Zhu Z, Ghose T, Iles S, Yang C, Lee S H, Fernandez L A, Lee C L
Department of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada.
Cancer Lett. 1994 Jan 15;76(1):31-44. doi: 10.1016/0304-3835(94)90131-7.
We investigated the pharmacokinetics, biodistribution and tumor localization of intravenously injected Dal B01 and Dal B02, two monoclonal antibodies (MoAbs) directed against tumor associated antigens on human chronic lymphocytic leukemia (CLL) B cells, and their F(ab)'2 fragments in nude mice bearing xenografts of the human B cell CLL line D10-1. More of the percentages of the injected dose (% ID) of these two MoAbs and their F(ab)'2 fragments specifically localized in the tumor xenografts than in normal tissues. Compared to intact MoAbs, their F(ab)'2 fragments had lower % ID in tumors and were cleared from circulation faster. Well-defined tumor images were obtained at 24 and 48 h after administration of [131I]Dal B02 F(ab)'2 fragment and at 96-192 h after administration of [131I]Dal B02. A comparison between intravenous and intraperitoneal routes of administration of [131I]Dal B02 did not reveal any difference in the localization of % ID in tumor or normal tissues.
我们研究了静脉注射Dal B01和Dal B02这两种针对人慢性淋巴细胞白血病（CLL）B细胞上肿瘤相关抗原的单克隆抗体（MoAbs）及其F(ab)'2片段在携带人B细胞CLL细胞系D10-1异种移植瘤的裸鼠体内的药代动力学、生物分布和肿瘤定位情况。与正常组织相比，这两种单克隆抗体及其F(ab)'2片段的注射剂量百分比（% ID）更多地特异性定位于肿瘤异种移植瘤中。与完整的单克隆抗体相比，它们的F(ab)'2片段在肿瘤中的% ID较低，且从循环中清除得更快。在注射[131I]Dal B02 F(ab)'2片段后24小时和48小时以及注射[131I]Dal B02后96 - 192小时获得了清晰的肿瘤图像。[131I]Dal B02静脉注射和腹腔注射途径之间的比较未显示肿瘤或正常组织中% ID定位存在任何差异。
